On Friday, Shares of EXCO Resources Inc (NYSE:XCO), lost -9.09% to $ 0.600.
EXCO Resources declared that its 2015 Annual Meeting of Shareholders has been recessed and will reconvene at 4 p.m., central time, on August 11, 2015, at the corporate office of EXCO, 12377 Merit Drive, First Floor Conference Center, Dallas, Texas.
EXCO’s Board of Directors continues to recommend that all EXCO shareholders approve each proposal presented at the Annual Meeting, and the Board remains committed to the transactions contemplated by the services and investment agreement reached with a partner of Bluescape Resources Company LLC. EXCO shareholders of record at the close of business on June 8, 2015 are entitled to vote at the Annual Meeting.
EXCO Resources, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development, and production of onshore oil and natural gas properties with a focus on shale resource plays in the United States.
Shares of Cardinal Health Inc (NYSE:CAH), inclined 0.35% to $85.08, during its last trading session.
Cardinal Health declared that its board of directors approved a quarterly dividend of $0.387 per share. This quarterly dividend will be payable on Oct. 15 to shareholders of record at the close of business on Oct. 1.
Cardinal Health, Inc., a healthcare services company, provides pharmaceutical and medical products and services in the United States and internationally. The company operates in two segments, Pharmaceutical and Medical.
At the end of Friday’s trade, Shares of Sealed Air Corp (NYSE:SEE), gained 1.19% to $55.27.
Sealed Air Corporation declared financial results for second quarter 2015. Commenting on these results, Jerome A. Peribere, President, and Chief Executive Officer, said, “Our second quarter 2015 performance demonstrates our continued focus on profitable growth and ongoing commitment to delivering innovative solutions to our customers. Net sales in the second quarter raised 3.3% on an organic basis and Adjusted EBITDA of $308 million was 17.2% of net sales. Adjusted EBITDA margins expanded by 280 basis points with margin expansion across all divisions. Given our performance in the first half of 2015 and our forecast for the remainder of the year, we are raising our outlook for Adjusted EBITDA, Adjusted EPS and Free Cash Flow.”
Unless otherwise stated, all results compare second quarter 2015 results to second quarter 2014 results. Year-over-year financial discussions present operating results as stated, and on an organic or constant dollar basis. Constant dollar performance excludes the impact of currency translation from all periods referenced. Organic performance excludes the impact of currency translation and the results from the divestiture of the North American foam trays and absorbent pads business, which was divested on April 1, 2015, from all periods referenced. Additionally, non-U.S. GAAP adjusted financial measures, such as Adjusted Earnings Before Interest Expense, Taxes, Depreciation and Amortization, Adjusted Net Earnings, Adjusted Diluted Earnings Per Share and Core Tax Rate, exclude the impact of special items, such as restructuring charges, Venezuela remeasurement, cash-settled stock appreciation rights granted as part of the Diversey acquisition and certain other infrequent or one-time items.
Sealed Air Corporation provides food safety and security, facility hygiene, and product protection solutions worldwide. The company’s Food Care segment offers integrated system solutions that incorporate equipment systems into customers operations; and packaging equipment systems that incorporate various options for loading, filling and dispensing, and retort and aseptic processing conditions.
Finally, Dyax Corp. (NASDAQ:DYAX), ended its last trade with 6.57 % gain, and closed at $23.83.
Dyax Corp., declared that executive administration will take part in the 2015 Wedbush PacGrow Global Healthcare Conference being held August 12-13, 2015 at Le Parker Meridien in New York City. The Company is planned to present on Wednesday, August 12 at 9:10am (ET).
Dyax Corp., a biopharmaceutical company, identifies, develops, and commercializes treatments for hereditary angioedema (HAE) and other plasma-kallikrein-mediated (PKM) disorders. It offers KALBITOR for the treatment of acute attacks of HAE.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
